Physician profile
Keith D Jorgensen
NPI 1023081601
$2,014.79
in general payments reported to CMS, 2019-2025
21 companies · $127 in 2025
The $127 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $786 · 2020: $38.30 · 2021: $610 · 2022: $323 · 2023: $31.02 · 2024: $99.50 · 2025: $127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $257.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $257.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerin Medical INC. | $625.69 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $319.24 | 2019-2024 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $222.26 | 2019-2025 | Tezspire |
| Glaxosmithkline, LLC. | $122.18 | 2019-2022 | |
| Greer Laboratories, INC. | $120.95 | 2019 | |
| Novartis Pharmaceuticals Corporation | $97.06 | 2019-2022 | |
| Stryker Corporation | $87.93 | 2019-2022 | |
| Genentech USA, INC. | $72.86 | 2019-2020 | |
| Shire North American Group INC | $42.85 | 2019 | |
| Janssen Biotech, INC. | $41.42 | 2024 | Tremfya, Stelara |
| Intersect Ent, INC. | $35.96 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.31 | 2025 | Eohilia, Entyvio |
| Alk-Abello, INC | $30.31 | 2019-2022 | |
| Pfizer INC. | $24.87 | 2019 | |
| Ucb, INC. | $24.07 | 2019-2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $23.21 | 2025 | Neffy |
| Genzyme Corporation | $22.68 | 2019 | |
| Merck Sharp & Dohme LLC | $19.64 | 2021 | |
| Phathom Pharmaceuticals, INC. | $17.33 | 2025 | Voquezna |
| Vertex Pharmaceuticals Incorporated | $14.55 | 2024 | |
| Optinose US, INC. | $14.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Jorgensen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.